Published in J Acquir Immune Defic Syndr on May 01, 2005
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol (2009) 2.39
Whither or wither microbicides? Science (2008) 2.17
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
Why primate models matter. Am J Primatol (2014) 2.05
Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother (2008) 1.68
Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med (2006) 1.56
Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. Nat Rev Microbiol (2010) 1.46
Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv Transl Res (2011) 1.44
Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40
High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis (2009) 1.38
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med (2012) 1.31
Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol (2011) 1.30
Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res (2009) 1.30
Animal models for microbicide studies. Curr HIV Res (2012) 1.17
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS One (2012) 1.16
Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther (2009) 1.12
Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect Dis (2010) 1.09
Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr Opin HIV AIDS (2008) 1.09
Contraception technology: past, present and future. Contraception (2012) 1.06
Polyanionic microbicides modify Toll-like receptor-mediated cervicovaginal immune responses. Antimicrob Agents Chemother (2009) 1.02
Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Antimicrob Agents Chemother (2006) 1.02
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol (2012) 1.01
Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology (2008) 0.97
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog (2008) 0.95
Animal models for microbicide safety and efficacy testing. Curr Opin HIV AIDS (2013) 0.94
Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics. Am J Reprod Immunol (2014) 0.93
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrob Agents Chemother (2009) 0.93
3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1. Antimicrob Agents Chemother (2010) 0.91
Mucosal immunity to HIV: a review of recent literature. Curr Opin HIV AIDS (2008) 0.89
Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis. Clin Vaccine Immunol (2006) 0.89
Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide. BMC Microbiol (2013) 0.89
Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol (2009) 0.88
Use of high-resolution confocal imaging of the vaginal epithelial microstructure to detect microbicide toxicity. J Infect Dis (2009) 0.87
Microbial products alter the expression of membrane-associated mucin and antimicrobial peptides in a three-dimensional human endocervical epithelial cell model. Biol Reprod (2012) 0.86
In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob Agents Chemother (2010) 0.86
Non-specific microbicide product development: then and now. Curr HIV Res (2012) 0.85
Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor. Int J Pharm (2013) 0.84
Nanoparticle transport from mouse vagina to adjacent lymph nodes. PLoS One (2012) 0.82
Quantitative assessment of microbicide-induced injury in the ovine vaginal epithelium using confocal microendoscopy. BMC Infect Dis (2012) 0.82
Monitoring vaginal epithelial thickness changes noninvasively in sheep using optical coherence tomography. Am J Obstet Gynecol (2013) 0.81
An anti-HIV microbicide comes alive. Proc Natl Acad Sci U S A (2005) 0.81
Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob Agents Chemother (2012) 0.81
Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response. PLoS One (2016) 0.81
L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide. Antimicrob Agents Chemother (2012) 0.80
Minocycline down-regulates topical mucosal inflammation during the application of microbicide candidates. PLoS One (2012) 0.80
Effects of feminine hygiene products on the vaginal mucosal biome. Microb Ecol Health Dis (2013) 0.80
In vivo evaluation of safety and toxicity of a Lactobacillus jensenii producing modified cyanovirin-N in a rhesus macaque vaginal challenge model. PLoS One (2013) 0.79
Dermaseptins and magainins: antimicrobial peptides from frogs' skin-new sources for a promising spermicides microbicides-a mini review. J Biomed Biotechnol (2009) 0.79
Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety. BMC Pharmacol Toxicol (2012) 0.78
Antiretroviral-based HIV prevention strategies for women. Expert Rev Anti Infect Ther (2010) 0.78
Characterization of commercially available vaginal lubricants: a safety perspective. Pharmaceutics (2014) 0.78
Biomedical approaches to HIV prevention. Alcohol Res Health (2010) 0.78
Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1. PLoS One (2012) 0.77
Safety and anti-HIV assessments of natural vaginal cleansing products in an established topical microbicides in vitro testing algorithm. AIDS Res Ther (2010) 0.77
An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission. J Pharm Sci (2015) 0.77
AF-2364 is a prospective spermicide candidate. Asian J Androl (2010) 0.76
Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 Gel. J Int AIDS Soc (2012) 0.76
The Effect of Commonly Used Excipients on the Epithelial Integrity of Human Cervicovaginal Tissue. AIDS Res Hum Retroviruses (2016) 0.75
Contraception and abortion. J R Soc Med (2007) 0.75
Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV. Infect Dis Obstet Gynecol (2014) 0.75
Recruitment of HIV-1 target cells at topical mucosal sites: a sensitive and early marker for determining the safety of microbicide candidates. Emerg Microbes Infect (2013) 0.75
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep (2005) 5.03
Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol (2006) 3.13
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med (2008) 2.81
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med (2008) 2.74
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol (2003) 2.20
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol (2005) 2.00
Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis (2002) 1.72
The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol (2005) 1.54
Greentree white paper: sexual violence, genitoanal injury, and HIV: priorities for research, policy, and practice. AIDS Res Hum Retroviruses (2012) 1.52
Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. J Acquir Immune Defic Syndr (2004) 1.41
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr (2013) 1.33
Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis (2004) 1.33
Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol (2009) 1.23
Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother (2013) 1.16
MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques. PLoS Pathog (2012) 1.07
Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res Hum Retroviruses (2006) 1.06
Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res (2010) 1.04
Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C. J Clin Microbiol (2008) 1.02
Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. AIDS Res Hum Retroviruses (2013) 0.98
Perceptions of reimbursement for clinical trial participation. J Empir Res Hum Res Ethics (2011) 0.98
Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. J Virol (2014) 0.94
In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate. Antiviral Res (2007) 0.89
Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies. Curr HIV/AIDS Rep (2014) 0.89
Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine (2010) 0.88
CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines. J Infect Dis (2004) 0.88
Interleukin-8 levels in seminal plasma in chronic prostatitis/chronic pelvic pain syndrome and nonspecific urethritis. BJU Int (2006) 0.88
A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins (2007) 0.87
DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. PLoS One (2011) 0.85
Non-specific microbicide product development: then and now. Curr HIV Res (2012) 0.85
Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. J Transl Med (2011) 0.82
Systemic and mucosal differences in HIV burden, immune, and therapeutic responses. J Acquir Immune Defic Syndr (2011) 0.81
A pilot study of treatment of bacterial vaginosis with a buffering vaginal microbicide. J Womens Health (Larchmt) (2003) 0.81
Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials. Sex Transm Dis (2012) 0.80
Microbicides 2006 conference. AIDS Res Ther (2006) 0.80
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. J Acquir Immune Defic Syndr (2016) 0.78
Mucosal immunity in the male and female reproductive tract and prevention of HIV transmission. Am J Reprod Immunol (2011) 0.78
Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference. J Transl Med (2010) 0.78
Hormone regulation of the mucosal environment in the reproductive tract and the prevention of HIV infection. Am J Reprod Immunol (2014) 0.76
Response to Morrison et al., "Hormonal contraception and the risk of HIV acquisition". AIDS (2007) 0.75
Critical need for appropriate mucosal sample collection to determine relational animal pharmacokinetic-pharmacodynamic models in HIV prevention. AIDS Res Hum Retroviruses (2013) 0.75
Antigen-presenting cells in HIV pathogenesis and therapy: summary of the October 17-18, 2002, Think Tank meeting. Clin Immunol (2002) 0.75
A plea for justice for jailed medical workers. Science (2006) 0.75
2010 Workshop: Mucosal immunity in the male and female reproductive tract and prevention of HIV transmission. AIDS Res Hum Retroviruses (2011) 0.75
Shaping the science of prevention. IAVI Rep (2014) 0.75